Clinical Trials Sponsored by Gracell Biotechnology Ltd.

Total 552 results

Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

An Exploratory Clinical Study of GC012F Injection for the Treatment of Refractory Generalized Myasthenia Gravis

Refractory Generalized Myasthenia Gravis

China
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Peking University Third Hospital
Gracell Biotechnology Ltd.

Not yet recruiting

A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Completed

A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

B-cell Non Hodgkin Lymphoma

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of FasT CAR-T GC012F Injection NDMM Patients

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Shanghai Changzheng Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Unknown

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Multiple Myeloma

China
Gracell Biotechnologies Ltd.

Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.; Beijing Lu Daopei Hospital

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
OrienGene Biotechnology Ltd.

Unknown

A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

Melanoma (Skin)

China
OrienGene Biotechnology Ltd.

Unknown

A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c

Melanoma

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Wuhan Rhegen Biotechnology Co., Ltd.
Shenzhen Rhegen Biotechnology Co., Ltd.; Wuhan Recogen Biotechnology Co., Ltd.

Withdrawn

A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

COVID-19 Pandemic
OriCell Therapeutics Co., Ltd.

Recruiting

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Relapsed and/or Refractory Multiple Myeloma

China
OriCell Therapeutics Co., Ltd.

Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Hepatocellular Carcinoma

China
Corregene Biotechnology Co., Ltd

Not yet recruiting

CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers

Cervical Cancer | Anal Cancer | Head and Neck Cancers | Other Solid Tumors
Sclnow Biotechnology Co., Ltd.

Not yet recruiting

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

Spinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6
Sclnow Biotechnology Co., Ltd.

Suspended

Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.

Cerebral Infarction

China
Genovate Biotechnology Co., Ltd.,

Completed

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

Intermittent Claudication

United States
Walvax Biotechnology Co., Ltd.

Enrolling by invitation

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Pneumococcal Disease, Invasive

Indonesia
TaiGen Biotechnology Co., Ltd.

Completed

Oral Nemonoxacin in Treating Elderly Patients With CAP

Community-acquired Pneumonia

Taiwan
Genovate Biotechnology Co., Ltd.,

Completed

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Intermittent Claudication

United States
TaiGen Biotechnology Co., Ltd.

Completed

A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

Healthy Volunteers
Genovate Biotechnology Co., Ltd.,

Completed

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Lupus Nephritis
TaiGen Biotechnology Co., Ltd.

Completed

Clinical Study on Oral Nemonoxacin Malate Capsules

Healthy Volunteers

China
Cellonis Biotechnology Co. Ltd.

Unknown

Stem Cell Therapy for Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

China
Genovate Biotechnology Co., Ltd.,

Completed

Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet

Type 2 Diabetes Mellitus

Taiwan
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd

Not yet recruiting

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Healthy

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China
Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
OriCell Therapeutics Co., Ltd.

Recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemostatic Disorders | Hemorrhagic Disorders | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood...

United States
Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Avistone Biotechnology Co., Ltd.

Not yet recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
RinuaGene Biotechnology Co., Ltd.

Not yet recruiting

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Cervical Intraepithelial Neoplasia Grade 2/3 | Human Papillomavirus Associated Intraepithelial Neoplasia | Human Papillomavirus Type 16 Infection | Human Papillomavirus Type 18 Infection
Ascendo Biotechnology Co., Ltd.

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

Metastatic Solid Tumor
Avistone Biotechnology Co., Ltd.

Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (Kannon)

Non-Small-Cell Lung Cancer

China

Clinical Trials Sponsored by Gracell Biotechnology Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations